NCT04217278 - A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT | Biotech Hunter

Enrollment

333

Participants

Timeline

Start Date

January 27, 2020

Primary Completion Date

March 31, 2025

Study Completion Date

March 31, 2025

Conditions

Acute Myeloid LeukaemiaHigh-risk Myelodysplastic Syndrome

Interventions

DRUG

Vyxeos

Vyxeos administered by intravenous infusion

DRUG

Fludarabine

Fludarabine administered by intravenous infusion

DRUG

Busulphan

Busulphan administered by intravenous infusion

DRUG

Thiotepa

Thiotepa administered by intravenous infusion

DRUG

Cytarabine

Cytarabine administered by intravenous infusion

Trial Locations (14)

Queen Elizabeth Hospital, Birmingham

University Hospitals Bristol, Bristol

Addenbrooke's Hospital, Cambridge

University Hospital of Wales, Cardiff

Queen Elizabeth Hospital Glasgow, Glasgow

St James' University Hospital, Leeds

Leicester Royal Infirmary, Leicester

Hammersmith Hospital, London

King's College Hospital, London

Manchester Royal Infirmary, Manchester

Freeman Hospital, Newcastle

Nottingham City Hospital, Nottingham

Churchill Hospital, Oxford

Derriford Hospital, Plymouth